Table 1.
Baseline clinicopathological characteristics (N = 644)
| Characteristics | Never smoker (n = 105) | Former smoker (n = 375) | Current smoker (n = 164) | P a |
|---|---|---|---|---|
| Age, median (range), y | 63 (25-87) | 69 (35-92) | 63 (38-88) | <.001 |
| Gender, No. (%) | .80 | |||
| Female | 60 (57.1) | 207 (55.2) | 88 (53.0) | |
| Male | 45 (42.9) | 168 (44.8) | 77 (47.0) | |
| Histology, No. (%) | .27 | |||
| Nonsquamous cell carcinoma | 97 (92.4) | 332 (88.5) | 141 (86.0) | |
| Squamous cell carcinoma | 8 (7.6) | 43 (11.5) | 23 (14.0) | |
| ECOG PSb, No. (%) | .48 | |||
| 0-1 | 82 (78.1) | 298 (79.5) | 123 (75.0) | |
| ≥2 | 22 (21.0) | 74 (19.7) | 40 (24.4) | |
| Unknown | 1 (1.0) | 3 (0.8) | 1 (0.6) | |
| PD-L1 TPSc, No. (%) | .07 | |||
| Negative | 20 (19.0) | 48 (12.8) | 12 (7.3) | |
| 1%-49% | 23 (21.9) | 86 (22.9) | 41 (25.0) | |
| ≥50% | 30 (28.6) | 137 (36.5) | 56 (34.1) | |
| Unknown | 32 (30.5) | 104 (27.7) | 55 (33.5) | |
| Lines of therapyd, No. (%) | <.001 | |||
| 1 | 18 (17.1) | 139 (37.1) | 59 (36.0) | |
| ≥2 | 87 (82.9) | 236 (62.9) | 105 (64.0) | |
| Median pack-yearse (IQR) | 0 (0) | 28 (25) | 40 (26.3) | <.001 |
| Median TMB (IQR), (mut/Mb) | 7.6 (6.1) | 9.9 (6.8) | 12.2 (7.7) | <.001 |
a
P values were based on a Wald test and were 2-sided. ECOG PS = Eastern Cooperative Oncology Group Performance Status; IQR = interquartile range; NA = not applicable; PD-L1 TPS = programmed death ligand-1 tumor proportion score; TMB = tumor mutation burden.
b
ECOG PS not available for 5 patients.
c
PD-L1 TPS not available for 191 patients.
d
1L present first-line treatment setting; 2 L+ present second-line treatment setting and beyond.
e
Smoking pack-years not available for 1 patient.